Cancer Research

Telomeres on chromosomes
#DNA #Lung cancer #MAIA Biotechnology #Oncology #Phase II trial

Positive efficacy updates for Phase II trial in non-small cell lung cancer

MAIA Biotechnology has shared positive updated data from its THIO-101 Phase II clinical trial evaluating its lead candidate, THIO, in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens.  In the trial, THIO was sequenced with Regeneron’s immune checkpoint inhibitor… Read More

#Cancer Research #News

#Antibody drug conjugate (ADC) #Cancer therapeutics #Cancer treatment #Interview #Oncology

Reducing cancer side effects through targeted therapies

Harry Palmer, Royal Commission of 1851 Industrial Fellow and PhD at University of Strathclyde, shares with DDW’s Megan Thomas how antibody-drug conjugates (ADCs) are revolutionising cancer treatment by offering targeted therapies with improved efficacy and reduced side effects, while addressing challenges in their development and paving the way for future… Read More

#Cancer Research #Exclusive Content

RNA strand
#Akribion Therapeutics #Oncology #RNA #Seed funding #Start-ups

€8m financing to pioneer RNA-guided cell depletion 

Akribion Therapeutics has exited stealth mode and completed a seed financing round, raising €8 million to accelerate the development of novel therapeutics.  The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds. … Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Vaccine vial and syringe
#Cancer vaccine #GSK #Immuno-oncology #Oncology #University of Oxford

Oxford and GSK launch £50m cancer vaccines programme

GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines.  The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, which unites expertise from four departments across the University and… Read More

#Business & Investment #Cancer Research #News

The tumour microenvironment
#Chemotherapy-resistance #Drug resistance #Oncology #The Institute of Cancer Research #Tumour microenvironment (TME)

Study reveals role of the secretome in cancer drug resistance

A new study has shown that non-cancerous cells positioned close to tumours can affect how cancer responds to treatment.   The researchers say factoring in the effects of these cells could improve drug development and provide new insights into the most effective use of existing cancer medications. … Read More

#Cancer Research #Editor's Choice #News

Cancer cell
#Cancer research #Cancer therapeutics #Oncology #World Cancer Day

World Cancer Day: Five key cancer drug discoveries of the year so far

For World Cancer Day, Diana Spencer collates five most significant oncology research advances so far in 2025. An AI drug discovery breakthrough Results of an in vivo mouse colorectal cancer model study have shown a 60% life extension for Oxford Drug Design’s first-in-class approach against multiple… Read More

#Cancer Research #News #Trending News

CAR-T therapy
#Allogene Therapeutics #Autoimmune disease #CAR-T #Cell therapy #FDA #Phase I trial

Allogeneic CAR-T therapy gets go-ahead for rheumatology trial

Allogene Therapeutics has been given the green light from the US Food and Drug Administration (FDA) for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR-T product.  The Phase I RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic… Read More

#Cancer Research #News #Regulatory

Soft tissue sarcoma
#Oncology #Phase II trial #Sarcoma #Vyome Therapeutics

Topical gel could be a breakthrough in cancer wounds

Vyome Therapeutics has shared interim results from its Phase II proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (MFW).  VT-1953, which exerts an immuno-anti-inflammatory effect by targeting TLR-MD2 and DNA gyrase, met its primary endpoint in this interim analysis, with patients… Read More

#Cancer Research #News

Quantum computer
#Artificial intelligence (AI) #Insilico Medicine #Oncology #Quantum computing

Quantum computing approach targets ‘undruggable’ protein

A study co-led by University of Toronto (U of T) researchers and Insilico Medicine has demonstrated the potential of quantum computing and artificial intelligence (AI) to transform the drug discovery pipeline.  “It’s an exciting time to be working at the interface of chemistry, quantum computing and AI. Read More

#Cancer Research #News #Trending News

Close up of vaccine syringe
#Cancer vaccine #HPV #Immunology / Virology & Vaccines #Oncology #Phase II trial #Women's health

Therapeutic HPV vaccine could eliminate precancerous cervical lesions

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).  Dr Refika Yigit, principal investigator and Oncological Gynaecologist at University… Read More

#Cancer Research #News

Two scientists working in a research laboratory
#Cancer Research UK #Oncology #Peptides #Phase II trial #Rare cancers

UK-Norwegian collaboration to trial peptide for rare cancer

Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase II clinical trial for patients with adrenocortical carcinoma (ACC).  CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets… Read More

#Business & Investment #Cancer Research #News

#Breast cancer #Cancer research #Clinical trials #Phesi

Breast cancer tops most-studied diseases, study finds 

Phesi has released the results of its annual global analysis of all clinical trials conducted in 2024, using data from its AI-driven Trial Accelerator platform (Figure 1). The analysis of 67,469 recruiting clinical trials reveals that breast cancer is the world’s most studied disease for the fourth consecutive year… Read More

#Cancer Research #News

Colorectal cancer
#Barts Institute #Bowel cancer #Colorectal cancer #Immunotherapy #Oncology #The Francis Crick Institute

CD74 level predicts immunotherapy response in bowel cancer

The amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy, new research has revealed.  If integrated into the clinic, the researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, say testing for… Read More

#Cancer Research #News #Trending News

Scan to diagnose head and neck cancer
#Cancer vaccine #Head and neck cancer #Oncology #Phase II trial #Scancell Holdings

Vaccine achieves early clinical validation in head and neck cancer

The combination of Scancell’s Modi-1 and a checkpoint blockade has shown promise in HPV negative head and neck squamous cell carcinoma (SCCHN) in an ongoing Phase IIa study.  The Phase IIa dose expansion ModiFY study is evaluating the safety, tolerability, and preliminary efficacy of Modi-1 in combination… Read More

#Cancer Research #News

Salivary glands
#Avacta #Head and neck cancer #Oncology #Peptide-drug conjugate #Phase I trial

Avacta’s peptide drug conjugate shrinks tumours in salivary gland cancer

Avacta has announced positive early efficacy data for its peptide drug conjugate, AVA6000, demonstrating clinically meaningful tumour shrinkage in patients with salivary gland cancer (SGC).  AVA6000 consists of doxorubicin chemotherapy conjugated with Avacta’s pre|CISION peptide, specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumour microenvironment. Read More

#Cancer Research #Editor's Choice #News